Q-omics provides the consensus-scored TRIM28 profile across patient tissues and cancer cell-line models. TRIM28 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TRIM28 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TRIM28 protein abundance shows 36,239 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where TRIM28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM28 survival associations across molecular data types. TRIM28 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM28 RNA expression–survival associations across cancer types. High TRIM28 expression shows unfavorable associations in MESO, ACC, LIHC, LUAD and KIRP, but favorable associations in UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TRIM28 RNA expression.
This table summarizes TRIM28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM28 shows higher tumor expression in COAD, HNSC, LIHC, STAD, BLCA and LUSC. The COAD box plot shows higher TRIM28 RNA expression in tumor versus normal tissue (log2 FC = +1.412, t-test p < 0.001).
This table shows molecular features associated with TRIM28 in patient tissues and cancer cell lines. In patient samples, TRIM28 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
